UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(D) of the
Securities
Exchange Act Of 1934
Date
of Report (Date of earliest event reported): July 29, 2014
Vantage
Health
(Exact
name of registrant as specified in its charter.)
Nevada |
|
000-55155 |
|
93-0659770 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation or organization) |
|
File Number) |
|
Identification No.) |
401
Warren St. Suite 200
Redwood
City, CA 94063
(Address
of principal executive offices) (Zip Code)
(650)
503-3570
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On
July 29th, 2014, Vantage Health (the “Company”) announced that the Board approved the appointment of Kevin Buckman MD
as Chairman and CEO of the Company to fill the vacancy left by the resignation on July 29, 2014 of Mr. Jeremy Barbera. On July
29, 2014, Mr. Jeremy Barbera, the Company’s Chairman and CEO, resigned as an officer and director of the Company. Mr. Barbera’s
resignation was not a result of any disagreements related to the Company’s operating, policies or practices. Mr. Barbera’s
resignation was due, in part, to certain matters involving a company with which Mr. Barbera was associated several years
ago. These matters are unrelated to the Company or any aspect of its technology or business. Mr. Barbera will remain as an employee
of the Company to focus on the scientific aspects of the Company’s technology in a non-executive capacity.
Prior
to July 29, 2014, Dr. Buckman, age 63, was previously the chief medical consultant for the Company. Dr. Buckman was issued 2,000,000
shares of common stock on March 12, 2014 as compensation for this service to the Company. Dr. Buckman has served as CEO and Chairman
of Viratech Corp., (OTC: VIRA) since November 4, 2012. Viratech is an open source biotechnology development company engaged in
the business of researching and developing cancer treatment protocols through the use of open source web based research networks.
In addition, from 1986 to the present, Dr. Buckman has been a staff physician at St. Joseph’s Medical Center in Stockton,
California and also at Lodi Memorial Hospital in Lodi, California.
Dr. Buckman has worked internationally to advance a number of
medical technologies with a focus on early detection of disease, with a primary focus on breast cancer and diabetes. His discoveries
of the roles of inflammation and abnormal cellular environments in cancers and immune diseases have made him a leader in the field.
His research has led to his interest in technologies in early diagnosis and treatments, especially in the field of breast cancer.
He recently published a book on the subject, Find and Stop Breast Cancer, as well as a book on solutions for diabetes and metabolic
syndrome, titled Find and Stop Diabetes.
Dr.
Buckman was not selected as a director or officer pursuant to any arrangement or understanding with any other person. The compensation
for Dr. Buckman for his new positions has not been determined.
The press
release announcing Mr. Barbera’s resignation and Dr. Buckman’s appointment is filed herewith as Exhibit 99.1 and is
incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release, dated July 29, 2014
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: August
4, 2014 |
Vantage
Health |
|
(Registrant) |
|
|
|
|
By: |
/s/ Dr. Kevin
Buckman |
|
|
Dr. Kevin Buckman |
|
|
Chief Executive
Officer |
EXHIBIT
INDEX
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release,
dated July 29, 2014 |
Dr
Kevin Buckman Named Chairman and CEO of Vantage Health
-Preliminary
human clinical trials are anticipated to begin next month-
Redwood
City, CA – July 29, 2014 – Vantage Health (the “Company”) (OTCQB: VNTH) today announced the appointment
of Kevin Buckman MD FAAIM, DAAUCM, MACOEM, MRO as Chairman and CEO of the Company.
The Company
also announced that Mr. Jeremy Barbera, its current Chairman and CEO, is resigning as an officer and director of the Company
and will focus on the scientific aspects of the Company’s technology in a non-executive capacity. This action is due, in
part, to certain matters involving a company with which Mr. Barbera was associated several years ago. These matters
are unrelated to the Company or any aspect of its technology or business
It is anticipated
that preliminary human trials for the Vantage Health Sensor will begin next month at Scripps Translational Science Institute,
paid for by a BioPharma partner of the Company. Mr. Barbera will continue to be Chairman and CEO of Nanobeak, which is the private
company majority shareholder of Vantage Health.
Dr.
Buckman completed his medical training in internal medicine in 1981. He began his research in 1977 in the fields of immunology,
cancer, diabetes, and chronic diseases. His discoveries of the roles of inflammation and abnormal cellular environments in
cancers and immune diseases have made him a leader in the field. His research has led to his interest in technologies in
early diagnosis and treatments, especially in the field of breast cancer. He recently published a book on the subject, Find
and Stop Breast Cancer, as well as a book on solutions for diabetes and metabolic syndrome, titled Find and Stop
Diabetes. He has worked internationally to advance a number of medical technologies with a focus on early detection of disease,
with a primary focus on breast cancer and diabetes.
Dr.
Buckman has served as Medical Director in various hospitals and institutions for over 25 years and has over 30 years of hospital
and clinical experience. He became Board Certified in Emergency Medicine and a Fellow of the American Board of Emergency Medicine
in 1990. In 2006 he became Board Certified in Urgent Care Medicine and a Diplomat. He also became a Fellow of the American Association
of Integrated Medicine, and a Certified Medical Review Officer.
Dr
Buckman was the first US Physician to be accepted into the European Group for Breast Cancer Screening. He received some post-graduate
training at Stanford University School of Business. He is also the Co-Founder of cancer.im, a 501(c)(3) non-profit organization
for cancer research. Dr. Buckman also serves as CEO of Viratech
Corp., which provides open source research using social networks.
#
# #
About
Vantage Health
Vantage
Health - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical
sensing residing within a small device attached to a smartphone. With its foundations in advanced nanotechnology, the Company’s
first product, the Vantage Health Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to
create the next generation mobile health application. The first mobile App is expected to be for lung cancer screening with additional
mobile healthcare Apps in the planning stages. The company has offices in Redwood City, CA and New York. For more information,
please visit http://www.vantagehealthinc.com
This press
release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among
other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with
respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also
include statements, among other things, concerning the efficacy, safety and intended utilization of the Company’s product
candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical
trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others,
the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or
efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, the Company may not obtain approval to
market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements
are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results
may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information,
and that actual future performance will be affected by a number of factors, including economic conditions, technological change,
regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary
significantly from what we currently foresee.
For a further
list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Annual
Report on Form 10-K and other periodic and other filings the Company files with the Securities and Exchange Commission and are
available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and the Company assumes
no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investors:
CSIR Group,
LLC.
Christine
Petraglia
212-386-7082
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024